Acrobiosystems Co

Acrobiosystems Co Forward P/E

The Forward P/E Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 59.46. In the previous year, Forward P/E Ratio was 79.51 — a change of -25.21% (lower).

Forward P/E

59.46

YoY

-25.21%

Last updated:

Forward P/E Ratio of Acrobiosystems Co is 2025 59.46 . Forward P/E Ratio of Acrobiosystems Co was 2024 79.51 . It decreases by -25.21% lower compared to the previous year.

The Acrobiosystems Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
868.08 CNY
Jan 1, 2019
886.79 CNY
Jan 1, 2020
84.96 CNY
Jan 1, 2021
56.51 CNY
Jan 1, 2022
48.32 CNY
Jan 1, 2023
64.10 CNY
Jan 1, 2024
79.51 CNY
Jan 1, 2025
59.46 CNY
The Acrobiosystems Co Forward P/E history
YEARForward P/EYoY
59.46-25.21%
79.51+24.03%
64.10+32.65%
48.32-14.49%
56.51-33.48%
84.96-90.42%
886.79+2.16%
868.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Forward P/E Ratio of Acrobiosystems Co is 59.46 in 2025.

Forward P/E Ratio of Acrobiosystems Co changed from 79.51 to 59.46, representing a -25.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co